Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 1

2(28.6%)

Early Phase 1

1(14.3%)

N/A

1(14.3%)

7Total

Phase 2(3)

Phase 1(2)

Early Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06689540Phase 1Recruiting

Mts105 for Advanced Hepatocellular Carcinoma

Role: lead

NCT05649163Unknown

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Role: lead

NCT05638828Early Phase 1Unknown

A Study of RD14-01 in Patients With Advanced Solid Tumors

Role: lead

NCT05227378Not ApplicableUnknown

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer

Role: lead

NCT04993378Unknown

Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy

Role: lead

NCT04640103Unknown

An Observational Study of Perioperative Immunotherapy in MSI-H Gastrointestinal Tumors

Role: lead

NCT03185988Phase 2Unknown

Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System

Role: lead

NCT01110941Phase 1Completed

Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China

Role: lead

NCT02016287Phase 2Unknown

Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer

Role: lead

NCT02016274Phase 2Unknown

Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer

Role: lead

All 10 trials loaded